In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access

Set Alert for Market Access

How To Make Your Drug Launch A Success

Recently launched drugs aren't meeting sales expectations and that's bad news for an industry whose revenues come from new products. Bain & Company surveyed senior launch executives to find the factors that lead to a successful launch.

BioPharmaceutical Commercial Market Access
Advertisement

Latest From Market Access

Pivotal US Medtech Value Initiative Gaining Traction

As the US health care system shifts from a fee-for-service to a value-based approach, In Vivo asks Don May, EVP for Payment and Healthcare Delivery Policy at AdvaMed, about the association's renewed push behind the value frameworks and what he hopes the industry's drive to build on patient engagement, among other aims, will achieve.

Market Access Medical Device

Medtech Stakeholders Must Speak The Common Language Of Innovation And Reward Value

The current system of paying for medical technology includes perverse incentives, which means that the full benefits that innovation can deliver are not being accessed. So says AdvaMed chairman Nadim Yared, who believes the US association's new "value framework" is the way forward for medtech stakeholders. A key element is ensuring that all players speak a common language – one that also recognizes and promotes appropriate ways of paying for innovation.

Market Access Medical Device

Medtronic’s Deal With Aetna Heralds New Value-Based Era

Medtronic's outcomes-based insulin pump supply deal with Aetna is the latest example of the medtech industry's shift toward value-based care.

Medical Device Diabetic Care

Access To Medicines Innovation: Seven Points To A Sustainable System

The Boston Consulting Group convened a roundtable of market access executives from leading biopharma companies in the US, Europe and Japan to reach consensus on how to finance the cost of health care. The group's working paper considers various approaches to financing high-quality care, with an initial emphasis on advocating for change among payers in Europe.

Market Access BioPharmaceutical

New Payment And Financing Models For Curative Regenerative Medicines

Cell and gene therapies that have the potential to cure require new approaches to value assessment, payment and financing. In the second of a series, the Alliance for Regenerative Medicine identifies potential payment models, highlights key stakeholder concerns and identifies the barriers that must be addressed to enable their integration across the health care system.

BioPharmaceutical Pricing Strategies

The Value Lab: Moving Value-Based Health Care From Theory To Practice

Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.

BioPharmaceutical Reimbursement
See All
UsernamePublicRestriction

Register